Targeting autophagy in autoimmune glomerular diseases

Area of Science:

• Cellular Biology
• Nephrology
• Immunology

Background:

• Autophagy is a cellular process for clearing damaged components, crucial for cell survival and homeostasis.
• Dysregulated autophagy is linked to autoimmune glomerular diseases, impacting kidney function.
• Hydroxychloroquine (HCQ) is a known autophagy inhibitor used in treating lupus nephritis.

Purpose of the Study:

• To explore the role of autophagy in kidney diseases and the therapeutic potential of autophagy modulation.
• To understand the mechanisms by which HCQ impacts inflammation and immune responses in glomerular diseases.
• To investigate the efficacy of HCQ and other autophagy-modulating drugs in various nephropathies.

Main Methods:

• Review of existing literature on autophagy in kidney disease.
• Analysis of HCQ's molecular mechanisms, including lysosomal function and immune cell modulation.
• Examination of studies on proteinuria reduction by HCQ and other agents in IgA nephropathy (IgAN), membranous nephropathy (MN), and focal segmental glomerulosclerosis (FSGS).

Main Results:

• Upregulated autophagy can promote inflammation in autoimmune kidney diseases.
• HCQ downregulates autophagy, reducing inflammation, T cell activation, and pro-inflammatory cytokine production.
• HCQ demonstrates potential in reducing proteinuria in lupus nephritis, IgAN, and MN.
• Other drugs targeting mitochondrial function or autophagy modulation may offer podocyte protection and reduce proteinuria in MN and FSGS.

Conclusions:

• Autophagy plays a complex role in kidney diseases, with dysregulation contributing to pathogenesis.
• HCQ's ability to inhibit autophagy offers therapeutic benefits by mitigating inflammation and immune dysregulation.
• Further research into autophagy modulation holds promise for novel treatments for various proteinuric kidney diseases.